RxDoctor Payments Data

Niral Patel, PA

Physician Assistant · Linden, NJNPI 1255527834

Payments from drug & device makers

$1,117in general payments, 2019–2025

Across 50 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$239
  • Medshape, Inc.$190
  • Lilly USA, LLC$131
  • Merck$94
  • GSK$80
  • Genentech USA, Inc.$69
  • plus $313 from 9 others

What the payments were for

  • Food & beverage$1,117100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,117 in reported general payments places this provider in the 75th percentile of 2,726 physician assistant providers in New Jersey.

See all physician assistant providers in New Jersey

Medicare billing

Part B allowed, 2024
$114,263
Medicare patients
132
Services billed
4,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide30$30,755
EliquisApixaban14$21,293
JanuviaSitagliptin Phosphate13$18,818
JardianceEmpagliflozin11$17,539
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,781
MyrbetriqMirabegron12$6,756
Atorvastatin Calcium267$2,199
Rosuvastatin Calcium68$1,614
Metformin Hcl125$984
Amlodipine Besylate192$947
Losartan Potassium101$833
Diclofenac Sodium33$739
Omeprazole52$713
Carvedilol45$637
Metoprolol Succinate83$613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$239$30,75530 claims
PfizerEliquis$15$21,29314 claims
MerckJanuvia$94$18,81813 claims
GSKTrelegy Ellipta$80$9,78115 claims
Astellas Pharma US IncMyrbetriq$37$6,75612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,726 physician assistant providers in New Jersey.

Other physician assistant in Linden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →